These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. The absence of chronic rejection in pediatric primary liver transplant patients who are maintained on tacrolimus-based immunosuppression: a long-term analysis. Jain A; Mazariegos G; Pokharna R; Parizhskaya M; Kashyap R; Kosmach-Park B; Smith A; Fung JJ; Reyes J Transplantation; 2003 Apr; 75(7):1020-5. PubMed ID: 12698091 [TBL] [Abstract][Full Text] [Related]
44. Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients. Penninga L; Penninga EI; Møller CH; Iversen M; Steinbrüchel DA; Gluud C Cochrane Database Syst Rev; 2013 May; (5):CD008817. PubMed ID: 23728681 [TBL] [Abstract][Full Text] [Related]
45. Conversion to belatacept maintenance immunosuppression in HIV-positive kidney transplant recipients. Santeusanio A; Bhansali A; De Boccardo G; Sehgal V; Delaney V; Florman S; Shapiro R Clin Transplant; 2020 Oct; 34(10):e14041. PubMed ID: 32654239 [TBL] [Abstract][Full Text] [Related]
46. Early post-transplant conversion from tacrolimus to belatacept for prolonged delayed graft function improves renal function in kidney transplant recipients. Wojciechowski D; Chandran S; Vincenti F Clin Transplant; 2017 May; 31(5):. PubMed ID: 28190259 [TBL] [Abstract][Full Text] [Related]
48. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial. Alloway RR; Vinks AA; Fukuda T; Mizuno T; King EC; Zou Y; Jiang W; Woodle ES; Tremblay S; Klawitter J; Klawitter J; Christians U PLoS Med; 2017 Nov; 14(11):e1002428. PubMed ID: 29135993 [TBL] [Abstract][Full Text] [Related]
49. Decreased incidence of acute rejection in adolescent kidney transplant recipients using antithymocyte induction and triple immunosuppression. Schwartz JJ; Ishitani MB; Weckwerth J; Morgenstern B; Milliner D; Stegall MD Transplantation; 2007 Sep; 84(6):715-21. PubMed ID: 17893604 [TBL] [Abstract][Full Text] [Related]
50. Developing New Immunosuppression for the Next Generation of Transplant Recipients: The Path Forward. Stegall MD; Morris RE; Alloway RR; Mannon RB Am J Transplant; 2016 Apr; 16(4):1094-101. PubMed ID: 26730885 [TBL] [Abstract][Full Text] [Related]
51. Elevated tacrolimus levels after treatment with nirmatrelvir/ritonavir (Paxlovid) for COVID-19 infection in a child with a kidney transplant. Young C; Papiro T; Greenberg JH Pediatr Nephrol; 2023 Apr; 38(4):1387-1388. PubMed ID: 35982345 [TBL] [Abstract][Full Text] [Related]
52. Induction type and outcomes for kidney graft and patient survival in recipients with prior lung transplantation in the United States. Riad S; Goswami U; Jackson S; Hertz M; Matas A J Heart Lung Transplant; 2020 Feb; 39(2):157-164. PubMed ID: 31837899 [TBL] [Abstract][Full Text] [Related]
53. Combination therapy of tacrolimus (FK506) with azathioprine and steroids in renal transplant recipients. Yoshimura N; Oka T; Ohmori Y; Yasumura T; Nakai I; Hamashima T; Nakajima H; Okamoto M; Nakamura K; Mizuta N Transplant Proc; 1998 Feb; 30(1):33-5. PubMed ID: 9474949 [No Abstract] [Full Text] [Related]
54. Use of tacrolimus eliminates acute rejection as a major complication following simultaneous kidney and pancreas transplantation. Peddi VR; Kamath S; Munda R; Demmy AM; Alexander JW; First MR Clin Transplant; 1998 Oct; 12(5):401-5. PubMed ID: 9787948 [TBL] [Abstract][Full Text] [Related]
55. Calcineurin inhibitors in renal transplantation: what is the best option? Tanabe K Drugs; 2003; 63(15):1535-48. PubMed ID: 12887261 [TBL] [Abstract][Full Text] [Related]
56. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781 [TBL] [Abstract][Full Text] [Related]
58. Addendum to Jeng L-B, et al. Efficacy and safety of everolimus with reduced tacrolimus in living-donor liver transplant recipients: 12-month results of a randomized multicenter study. Am J Transplant. 2018;18:1435-1446. Am J Transplant; 2022 Oct; 22(10):2489-2490. PubMed ID: 36196491 [No Abstract] [Full Text] [Related]
59. Tacrolimus in pediatric renal transplantation: a review. Shapiro R Pediatr Transplant; 1998 Nov; 2(4):270-6. PubMed ID: 10084728 [TBL] [Abstract][Full Text] [Related]
60. Randomized controlled trial assessing the impact of everolimus and low-exposure tacrolimus on graft outcomes in kidney transplant recipients. Taber DJ; Chokkalingam A; Su Z; Self S; Miller D; Srinivas T Clin Transplant; 2019 Oct; 33(10):e13679. PubMed ID: 31365151 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]